Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Study sponsor: Xencor, Inc. · XNCR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-02-21Actual
Enrollment · participants3Actual
Source updated2024-04-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.